Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis.

Blood - 15 Jul 2010

Huls Gerwin, Mulder André B, Rosati Stefano, van de Loosdrecht Arjan A, Vellenga Edo, de Wolf Joost T M

Abstract excerpt

Patients with refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) are difficult to treat because the cytoreductive treatment might be beneficial for the thrombocytosis component but harmful for the RARS component. As lenalidomide has shown to be efficacious in both myelodysplasti...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia, Sideroblastic
Share to Erythropoietin
Share to Lenalidomide

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pulmonary Embolism

Share to Pyridoxine

Share to Thalidomide

Share to Thrombocytosis

Share to Vitamin B Complex

Source

Identifiers

PMID: 20194893
DOI: 10.1182/blood-2010-01-263087

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Prepared record publication-20194893-2026-09-05.1. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis.PMID 20194893Read ↗

Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis.Semantic proximity Read ↗

Refractory anemia with ring sideroblasts associated with marked thrombocytosis: a mixed group exhibiting a spectrum of morphologic findings.Semantic proximity Read ↗

Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic featuresSemantic proximity Read ↗

Refractory anemia with ring sideroblasts and RARS with thrombocytosis.Semantic proximity Read ↗

Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.Semantic proximity Read ↗

Refractory anemia with ringed sideroblasts and thrombocytosis without JAK2 V617F mutation: report of three cases.Semantic proximity Read ↗

Refractory anemia with ring sideroblasts associated with thrombocytosis (RARS-T).Semantic proximity Read ↗

A phase-2 trial of low-dose pomalidomide in myelofibrosis.Semantic proximity Read ↗

JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.Semantic proximity Read ↗

Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis.Semantic proximity Read ↗

Refractory anemia with ringed sideroblasts in children: two diseases with a similar phenotype?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.